IMP-288

Known as: IMP 288, IMP288 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2016
012320102016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Pretargeted radioimmunotherapy (PRIT) with the β-emitting radionuclide 177Lu is an attractive approach to treat carcinoembryonic… (More)
  • figure 1
  • figure 6
Is this relevant?
2016
2016
Earlier clinical studies reported a high sensitivity of pretargeted immunoscintigraphy using murine or chimeric… (More)
Is this relevant?
2015
2015
OBJECTIVES A phase I pretargeted radioimmunotherapy trial (EudractCT 200800603096) was designed in patients with metastatic lung… (More)
Is this relevant?
2014
2014
Pretargeted radioimmunotherapy (PRIT) with bispecific antibodies (bsMAb) and a radiolabeled peptide reduces the radiation dose to… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
UNLABELLED TROP-2 is a pancarcinoma marker that is expressed at high levels in many epithelial cancers, including prostate cancer… (More)
Is this relevant?
2014
2014
Pretargeting with bispecific antibodies and radiolabeled hapten-peptides could be used to specifically target tumors with high… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
TF12 is a trivalent bispecific antibody that consists of two anti-TROP-2 Fab fragments and one anti-histamine-succinyl-glycine… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
Background:Radiolabelled antibody targeting of cancer is limited by slow blood clearance. Pretargeting with a non-radiolabelled… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2012
2012
UNLABELLED The prospects for using pretargeted immuno-SPECT to monitor the response to pretargeted radioimmunotherapy were… (More)
Is this relevant?
2010
2010
UNLABELLED Pretargeted radioimmunotherapy (PRIT) with bispecific antibodies in combination with a radiolabeled peptide reduces… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 5
  • figure 6
Is this relevant?